Sphingomyelin in erythrocyte membranes increases the total cholesterol content of erythrocyte membranes in patients with acute coronary syndrome

Coronary Artery Disease

Volumn 24, Issue 5, 2013, Pages 361-367

  Zhang, Jianhua ^a   Tu, Kexiang ^a   Xu, Yan ^a   Pan, Lingxin ^a   Wu, Changhao ^b   Chen, Xuhua ^a   Wu, Mengzuo ^a   Cheng, Ziping ^a   Chen, Bin ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

acute coronary syndrome; sphingomyelin content of erythrocyte membranes; total cholesterol content of erythrocyte membranes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; SPHINGOMYELIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CARDIAC PATIENT; CHOLESTEROL BLOOD LEVEL; CONFOUNDING VARIABLE; CONTROLLED STUDY; DISEASE COURSE; ELECTROCARDIOGRAM; ERYTHROCYTE MEMBRANE; EXERCISE TEST; FEMALE; HEART INFARCTION; HEART MUSCLE PERFUSION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; ST SEGMENT; STABLE ANGINA PECTORIS; THORAX PAIN; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANGINA, STABLE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL; CORONARY ANGIOGRAPHY; DISEASE PROGRESSION; ERYTHROCYTE MEMBRANE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTORS; SPHINGOMYELINS; UP-REGULATION;

EID: 84880810101     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328362228f     Document Type: Article

References (29)

1. Seimiya K, Inami S, Takano M, Ohba T, Sakai S, Takano T, et al. Significance of plaque disruption sites in acute coronary syndrome. J Nippon Med Sch 2006; 73:141-148.
2. Pasterkamp G, Virmani R. The erythrocyte: a new player in atheromatous core formation. Heart 2002; 88:115-116.
3. Davies MJ, Richardson PD,Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69:377-381.
4. Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996; 16:4-11.
5. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349:2316-2325.
6. Yu MM, Xu Y, Zhang JH, Wang CH, Wang XC, Cheng ZP, et al. Total cholesterol content of erythrocyte membranes levels are associated with the presence of acute coronary syndrome and high sensitivity C-reactive protein. Int J Cardiol 2010; 145:57-58.
7. Zhang J, Pan L, Xu Y, Wu C, Wang C, Cheng Z, et al. Total cholesterol content of erythrocyte membranes in acute coronary syndrome: correlation with apolipoprotein A-I and lipoprotein (a). Coron Artery Dis 2011; 22:145-152.
8. Tziakas DN, Kaski JC, Chalikias GK, Romero C, Fredericks S, Tentes IK, et al. Total cholesterol content of erythrocyte membranes is increased in patients with acute coronary syndrome: a new marker of clinical instability? J AmColl Cardiol 2007; 49:2081-2089.
9. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G,Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 1996; 98:1455-1464.
10. Ohvo-Rekila H, Ramstedt B, Leppimaki P, Slotte JP. Cholesterol interactions with phospholipids in membranes. Prog Lipid Res 2002; 41:66-97.
11. Comte J, Maisterrena B, Gautheron DC. Lipid composition and protein profiles of outer and inner membranes from pig heart mitochondria. Comparison with microsomes. Biochim Biophys Acta 1976; 419:271-284.
12. Tziakas DN, Chalikias GK, Antonoglou CO, Veletza S, Tentes IK, Kortsaris AX, et al. Apolipoprotein E genotype and circulating interleukin-10 levels in patients with stable and unstable coronary artery disease. J Am Coll Cardiol 2006; 48:2471-2481.
13. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959-969.
14. Cannon CP, Battler A, Brindis RG, Cox JL, Ellis SG, Every NR, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001; 38:2114-2130.
15. Arroyo-Espliguero R, Avanzas P, Cosin-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004; 25:401-408.
16. Miwa S, Inouye M, Ohmura C, Mitsuhashi N, Onuma T, Kawamori R. Relationship between carotid atherosclerosis and erythrocyte membrane cholesterol oxidation products in type 2 diabetic patients. Diabetes Res Clin Pract 2003; 61:81-88.
17. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
18. Hojjati MR, Jiang XC. Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine. J Lipid Res 2006; 47:673-676.
19. Karthikeyan G, Teo KK, Islam S, McQueen MJ, Pais P, Wang X, et al. Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. J Am Coll Cardiol 2009; 53:244-253.
20. Bismuth J, Lin P, Yao Q, Chen C. Ceramide: a common pathway for atherosclerosis? Atherosclerosis 2008; 196:497-504.
21. Alewijnse AE, Peters SL. Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur J Pharmacol 2008; 585:292-302.
22. Devlin CM, Leventhal AR, Kuriakose G, Schuchman EH,Williams KJ, Tabas I. Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol 2008; 28:1723-1730.
23. Wang X, Dong J, Zhao Y, Li Y, Wu M. Adenovirus-mediated sphingomyelin synthase 2 increases atherosclerotic lesions in ApoE KO mice. Lipids Health Dis 2011; 10:7.
24. Fan Y, Shi F, Liu J, Dong J, Bui HH, Peake DA, et al. Selective reduction in the sphingomyelin content of atherogenic lipoproteins inhibits their retention in murine aortas and the subsequent development of atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30:2114-2120.
25. Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000; 20:2614-2618.
26. Nelson JC, Jiang XC, Tabas I, Tall A, Shea S. Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis. Am J Epidemiol 2006; 163:903-912.
27. Yeboah J, McNamara C, Jiang XC, Tabas I, Herrington DM, Burke GL, et al. Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30:628-633.
28. Slotte JP, Bierman EL. Depletion of plasma-membrane sphingomyelin rapidly alters the distribution of cholesterol between plasma membranes and intracellular cholesterol pools in cultured fibroblasts. Biochem J 1988; 250:653-658.
29. Okwu AK, Xu XX, Shiratori Y, Tabas I. Regulation of the threshold for lipoprotein-induced acyl-CoA:cholesterol O-acyltransferase stimulation in macrophages by cellular sphingomyelin content. J Lipid Res 1994; 35:644-655. Research of Education Natural Science Foundation